Crinetics Pharmaceuticals, Inc. Sale of Stock, Consideration Received on Transaction
Crinetics Pharmaceuticals, Inc. (CRNX) reported Sale of Stock, Consideration Received on Transaction of $7.80 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Notes
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2022-11-14
- Crinetics Pharmaceuticals, Inc. sale of stock, consideration received on transaction for the quarter ending 2022-09-30 was $0.00.
- Crinetics Pharmaceuticals, Inc. sale of stock, consideration received on transaction for the quarter ending 2021-09-30 was $0.00.
| Period end | Sale of Stock, Consideration Received on Transaction 3 month | Sale of Stock, Consideration Received on Transaction 6 month | Sale of Stock, Consideration Received on Transaction 9 month |
|---|---|---|---|
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $7.80M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $7.80M 10-Q · filed 2022-08-12 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $2.40M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $2.40M 10-Q · filed 2022-08-12 |